Connect Sign In
Prostate Specific Antigen, Total - Medicare Screening
Ordering Recommendation
Preferred initial screening test for prostate cancer in conjunction with digital rectal exam. Use to monitor patients for recurrence of cancer.
New York DOH Approval Status
Specimen Required
Serum Separator Tube (SST). Also acceptable: Green (lithium heparin), Lavender (K2EDTA), or Pink (K2EDTA).
Transport 1 mL serum or plasma in an ARUP Standard Transport Tube. (Min: 0.5 mL)
Frozen.
Hemolyzed specimens.
Ambient: 24 hours; Refrigerated: 5 days; Frozen: 6 months
Methodology
Quantitative Electrochemiluminescent Immunoassay
Performed
Sun-Sat
Reported
Within 24 hours
Reference Interval
0.0-4.0 ng/mL
Interpretive Data
The Roche PSA electrochemiluminescent immunoassay is used. Results obtained with different test methods or kits cannot be used interchangeably. The Roche PSA method is approved for use as an aid in the detection of prostate cancer when used in conjunction with a digital rectal exam in individuals with a prostate age 50 years and older. The Roche PSA is also indicated for the serial measurement of PSA to aid in the prognosis and management of prostate cancer patients. Elevated PSA concentrations can only suggest the presence of prostate cancer until biopsy is performed. PSA concentrations can also be elevated in benign prostatic hyperplasia or inflammatory conditions of the prostate. PSA is generally not elevated in healthy individuals or individuals with nonprostatic carcinoma.
FDA
Note
This test should be ordered for screening purposes for Medicare patients only.
Hotline History
CPT Codes
G0103
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 0070234 | Prostate Spec Ag Total Screen | 83112-3 |
Aliases
- PSA
- Screen for Prostate Specific Ag
- sPSA
